• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Juno Biomedical joins Singularity University Accelerator

Juno Biomedical joins Singularity University Accelerator

May 16, 2016
CenterWatch Staff

Juno Biomedical, a startup developing a revolutionary technology to repair damaged brain tissue in stroke victims, was selected by Singularity University to participate in their highly selective SU Labs Startup Accelerator program. The program, which kicked-off last week, only selects startups using cutting-edge technologies to solve humanity’s grand challenges.

With its mission to improve quality of life for patients after neurological damage, Juno Biomedical joined other pioneering startups in Silicon Valley last week. CEO Trisha Pfluger expects that the accelerator will facilitate the development of Juno Biomedical’s long-term strategy and improve its access to capital.

“Singularity University’s program is the only accelerator where your homework is to better the lives of at least 1 billion people worldwide,” Pfluger said. “The program gives us uncommon access to a new network of resources and connections—we’ve already been introduced to a number of venture capitalists, innovators and industry leaders.”

Juno Biomedical’s technology, developed in part at UC Davis, could change the standard of care for survivors of stroke and brain injury. With more than 30 million stroke survivors worldwide there is a substantial need for their technology. With no current treatment to repair brain tissue damage, stroke survivors must adapt to their disability. Juno Biomedical’s CELLTech technology is intended to heal brain tissue damage by facilitating new neural connections between functional cells and has been shown in pre-clinical trials to be safe and effective. This revolutionary technology could return stroke and brain injury patients who currently have no other options to a state of well-being.

Juno Biomedical was launched in 2014 in Davis, California, by scientist and inventor Trisha Pfluger with an aim to transform the standard of care for persons with neurological impairment. Founded on the idea that patient care should heal the underlying cause of disease rather than only alleviate the symptoms, Juno Biomedical endeavors to integrate technologies such as digital patient monitoring, bioelectric therapy, and tissue regeneration to create an innovative medical device that can heal brain tissue damage. Now headquartered in Mountain View, California, the company is pioneering advances not only in healing, but in personalized, in-home medical care.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing